FDA expands selumetinib approval to include pediatric patients as young as 1 year with inoperable plexiform neurofibromas. The U.S. Food and Drug Administration (FDA) has approved selumetinib (Koselugo) granules and capsules for pediatric patients...
The FDA has approved a delivery system that, once inserted into the bladder, delivers a local dose of the drug gemcitabine. The U.S. Food and Drug Administration (FDA) has approved a gemcitabine intravesical system...
The FDA has approved zongertinib for patients with unresectable or metastatic non-squamous non-small cell lung cancer that has HER2 tyrosine kinase domain mutations and has undergone prior treatment. The U.S. Food and Drug Administration...
The FDA has approved the first-in-class therapeutic dordaviprone for certain adult and pediatric patients with H3 K27M-mutated diffuse midline glioma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to dordaviprone (Modeyso)...
The FDA has approved sunvozertinib for certain patients with EGFR-mutated non-small Cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sunvozertinib (Zegfrovy) for the treatment of adult patients...
The FDA has approved linvoseltamab-gcpt for certain patients with heavily pretreated multiple myeloma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for the treatment of adult patients with...
The FDA has approved datopotamab deruxtecan-dlnk for certain patients with non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway) for the treatment of adult...
The FDA has approved tafasitamab-cxix for certain patients with follicular lymphoma. The U.S. Food and Drug Administration (FDA) has approved tafasitamab-cxix (Monjuvi) in combination with lenalidomide (Revlimid) and rituximab (Rituxan) for the treatment of...
The FDA has approved pembrolizumab for certain patients with previously untreated head and neck cancer. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) for the treatment of adult patients with resectable...
The FDA has approved mitomycin intravesical solution for certain patients with recurrent non-muscle invasive bladder cancer. The U.S. Food and Drug Administration (FDA) has approved mitomycin intravesical solution (Zusduri) for the treatment of adult...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More